SAGA Diagnostics, a pioneer in blood-based cancer detection and precision medicine redefining the standard for ultra-sensitive and early molecular residual disease (MRD) detection, will present five ...

Using CD22/CD19 CAR T-cell therapy followed by autologous stem cell transplant (ASCT) showed promising results in patients ...

Adding blinatumomab to consolidation chemotherapy for B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in patients without measurable residual disease (MRD) led to improvements in overall and ...

The CEPHEUS trial is a trial for newly diagnosed multiple myeloma patients who are not eligible for stem cell transplantation, or in whom a transplant was deferred. And 395 patients were randomized ...

MRD detection via ctDNA poses challenges in managing breast cancer patients in complete remission, especially when imaging is ...

Minimal residual disease (MRD)—minute populations of cancer cells undetectable by conventional imaging—remains the chief ...

NEW ORLEANS -- Consolidation chemotherapy with blinatumomab (Blincyto) improved overall survival (OS) in patients with newly diagnosed measurable residual disease (MRD)-negative B-lineage acute ...

A Darzalex-based regimen improved MRD negativity rates compared with VRd in patients with newly diagnosed, transplant-eligible multiple myeloma. Darzalex (daratumumab) plus Velcade (bortezomib), ...

Iclusig plust reduced-intensity bested Gleevec when it came to MRD-negative complete remission in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Adding Iclusig (ponatinib ...

Researchers found that the outcomes were excellent for the 178 end of first consolidation measurable residual disease (MRD)-negative patients, regardless of MRD results at later time points. HealthDay ...

CHICAGO -- Patients with undetectable disease after induction therapy for newly diagnosed multiple myeloma (NDMM) did not have significantly better outcomes with a stem-cell transplant versus drug ...